JNJ

151.1

+1.39%↑

UNH

287.08

+8.27%↑

ABBV

182.7

+1.73%↑

NVO

64.19

-2.96%↓

ABT

134.74

+1.67%↑

JNJ

151.1

+1.39%↑

UNH

287.08

+8.27%↑

ABBV

182.7

+1.73%↑

NVO

64.19

-2.96%↓

ABT

134.74

+1.67%↑

JNJ

151.1

+1.39%↑

UNH

287.08

+8.27%↑

ABBV

182.7

+1.73%↑

NVO

64.19

-2.96%↓

ABT

134.74

+1.67%↑

JNJ

151.1

+1.39%↑

UNH

287.08

+8.27%↑

ABBV

182.7

+1.73%↑

NVO

64.19

-2.96%↓

ABT

134.74

+1.67%↑

JNJ

151.1

+1.39%↑

UNH

287.08

+8.27%↑

ABBV

182.7

+1.73%↑

NVO

64.19

-2.96%↓

ABT

134.74

+1.67%↑

Search

Eli Lilly and Co.

Open

BrancheGesundheitswesen

755 2.6

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

731.21

Max

755.43

Schlüsselkennzahlen

By Trading Economics

Einkommen

-6.1B

2.8B

Verkäufe

-804M

13B

KGV

Branchendurchschnitt

61.579

56.602

EPS

3.34

Dividendenrendite

0.82

Gewinnspanne

21.678

Angestellte

47,000

EBITDA

-2B

4.2B

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+37.39% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.82%

2.45%

Nächstes Ergebnis

6. Aug. 2025

Nächste Dividendenausschüttung

10. Juni 2025

Nächstes Ex-Dividendendatum

16. Mai 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-149B

678B

Vorheriger Eröffnungskurs

752.4

Vorheriger Schlusskurs

755

Nachrichtenstimmung

By Acuity

63%

37%

335 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Eli Lilly and Co. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Mai 2025, 11:24 UTC

Ergebnisse

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

22. Apr. 2025, 09:26 UTC

Wichtige Markttreiber

Novo Nordisk Shares Fall After Data From New Eli Lilly Pill

18. Apr. 2025, 15:57 UTC

Wichtige Markttreiber

Eli Lilly CEO Ricks Warns Against Unintentionally Raising Prices as Weight-Loss Pill Nears Market Launch

12. Mai 2025, 22:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12. Mai 2025, 18:45 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12. Mai 2025, 17:14 UTC

Top News

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7. Mai 2025, 17:01 UTC

Top News

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7. Mai 2025, 13:56 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7. Mai 2025, 11:18 UTC

Ergebnisse

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7. Mai 2025, 09:30 UTC

Top News

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6. Mai 2025, 20:30 UTC

Top News

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4. Mai 2025, 04:05 UTC

Akquisitionen, Fusionen, Übernahmen

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1. Mai 2025, 21:07 UTC

Market Talk

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1. Mai 2025, 14:07 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 12:47 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1. Mai 2025, 12:00 UTC

Top News

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1. Mai 2025, 11:58 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 11:06 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1. Mai 2025, 10:48 UTC

Ergebnisse

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1. Mai 2025, 10:48 UTC

Ergebnisse

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly 1Q Adj EPS $3.34 >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly 1Q Net $2.76B >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly 1Q Rev $12.73B >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly 1Q EPS $3.06 >LLY

1. Mai 2025, 10:45 UTC

Ergebnisse

Eli Lilly Sees FY Adj EPS $20.78-Adj EPS $22.28 >LLY

30. Apr. 2025, 09:30 UTC

Top News

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

28. Apr. 2025, 13:58 UTC

Top News

IBM, Apple, Eli Lilly: Tracking Corporate Spending Pledges Under Trump -- WSJ

22. Apr. 2025, 09:31 UTC

Heiße Aktien

Stocks to Watch Tuesday: Tesla, Novo Nordisk, Hertz -- WSJ

17. Apr. 2025, 18:27 UTC

Top News

Lilly's First Pill for Diabetes, Weight Loss Shows Positive Study Results -- Update

Peer-Vergleich

Kursveränderung

Eli Lilly and Co. Prognose

Kursziel

By TipRanks

37.39% Vorteil

12-Monats-Prognose

Durchschnitt 983.13 USD  37.39%

Hoch 1,124 USD

Tief 700 USD

Basierend auf 20 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Eli Lilly and Co. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

20 ratings

18

Buy

1

Halten

1

Sell

Technischer Score

By Trading Central

N/A / 884.54Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

335 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.